000			04089nam a22004095i 4500
999			_c392039 _d392039
001			392039
003			ES-MaUEC
005			20231104161345.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			120106s2012 xxu| o |||| 0|eng d
020			_a9781617795206
024	7		_a10.1007/978-1-61779-520-6 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRM301.25 _b2012 EB
245	0	0	_aStructure-Based Drug Discovery _cedited by Leslie W. Tari
250			_a1st edition 2012
264		1	_aTotowa, NJ _bHumana Press _c2012
300			_a1 recurso en línea (IX, 385 páginas) _b130 ilustraciones, 5 ilustraciones a color
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aMethods in Molecular Biology _x1940-6029 _v841
505	0		_aThe Utility of Structural Biology in Drug Discovery -- Genetic Construct Design and Recombinant Protein Expression for Structural Biology -- Purification of Proteins for Crystallographic Applications -- Protein Crystallization for Structure-Based Drug Design -- X-Ray Sources and High-Throughput Data Collection Methods -- The Use of Molecular Graphics in Structure-Based Drug Design -- Crystallographic Fragment Screening -- The Role of Enzymology in a Structure-Based Drug Discovery Program: Bacterial DNA Gyrase -- Leveraging Structural Information for the Discovery of New Drugs: Computational Methods -- Chemical Informatics - Using Molecular Shape Descriptors in Structure-Based Drug Design -- Accounting for Solvent in Structure-Based Drug Design -- Structure-Based Drug Design on Membrane Protein Targets: Human Integral Membrane Protein 5-Lipoxygenase-Activating Protein -- Application of SBDD to the Discovery of New Antibacterial Drugs -- Leveraging SBDD in Protein Therapeutic Development: Antibody Engineering -- A Medicinal Chemistry Perspective on Structure-Based Drug Design and Development.
520			_aThe last decade has seen the confluence of several enabling technologies that have allowed protein crystallographic methods to live up to their true potential. Taken together, the numerous recent advances have made it possible to tackle difficult biological targets with a high probability of success: intact bacterial ribosomes have been structurally elucidated, as well as eukaryotic trans-membrane proteins like the potassium channel and GPCRs. It is now possible for medicinal chemists to have access to structural information on their latest small molecule candidates bound to the therapeutic target within days of compound synthesis, allowing structure guided ligand optimization to occur in "real time". Structure-Based Drug Discovery presents an array of methods used to generate crystal structures of biological macromolecules, how to leverage the structural information to design novel ligands anew, and how to iteratively optimize hits and convert them to leads. Written in the successful Methods in Molecular Biology™ series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and notes on troubleshooting and avoiding known pitfalls.   Authoritative and easily accessible, Structure-Based Drug Discovery aims to provide scientists interested in adding SBDD to their arsenal of drug discovery methods with well-honed, up-to-date methodologies.
988			_aSpringer_Protocols_2012
650		7	_2embne _9161127 _aTecnología farmacéutica
650		7	_2embne _9669891 _aProteínas _xEstructura
776	0	8	_iPrinted edition: _z9781617795190
776	0	8	_iPrinted edition: _z9781617795213
776	0	8	_iPrinted edition: _z9781493961375
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-1-61779-520-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b11/2023 _dz _eIG _zSI